IPCA Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 15.7%)
- Efficient capital deployment (ROCE 17%)
- Attractively valued vs sector (P/E 36.1x vs industry 50.2x)
- Low debt relative to equity (D/E 0.1x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
IPCALAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.29% | 46.30% | 46.30% | 46.30% | 44.72% | 44.72% |
| FII | 10.27% | 10.51% | 10.85% | 10.83% | 11.06% | 10.75% |
| DII | 34.19% | 34.05% | 33.46% | 33.90% | 35.36% | 35.73% |
| Public | 8.93% | 8.82% | 9.07% | 8.64% | 8.53% | 8.45% |
| Govt | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 6 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 2 Per Share
Interim Dividend - Rs 2 Per Share
Annual General Meeting/Dividend - Rs 2 Per Share
Interim Dividend - Rs 2 Per Share
Latest News
All newsIPCA Labs reports Q1FY26 financial results.
*IPCA Labs reports Q1FY26 financial results.* The company has released its financial performance for the quarter ended June 30, 2026. Key metrics include revenue of **₹428 crore** and net profit of **₹34.2 crore**. Results reflect steady growth in domestic and international markets. 📊 *STOCKS:* $IPCALABORATORY | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Earnings
IPCA Laboratories receives credit rating update
*IPCA Laboratories receives credit rating update.* The company’s latest credit assessment has been filed with the exchange. **No financial figures or rating changes** were detailed in the headline. Further specifics are expected in the full report. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #credit_rating
IPCA Labs holds analyst and investor meet.
*IPCA Labs holds analyst and investor meet.* The company conducted a conference call with institutional investors and analysts to discuss business updates. No financial figures or major announcements were disclosed. The event is part of routine investor engagement. 📊 *STOCKS:* $IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
IPCA Labs to host analyst and investor meet
*IPCA Labs to host analyst and investor meet* to discuss business updates and strategy. The event aims to enhance investor engagement and provide insights into recent performance. No financial announcements or guidance revisions were disclosed. The move signals transparency but lacks immediate market-moving details. 📊 *STOCKS:* $IPCALABORATORY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
IPCA Labs publishes mandatory newspaper notice
*IPCA Labs publishes mandatory newspaper notice.* This is a routine corporate filing requirement with no material business update. Such notices are typically issued for regulatory or legal disclosures. No financial or operational impact is expected. 📊 *STOCKS:* IPCALABORATORY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporatefiling
IPCA Labs files Business Responsibility and Sustainability Report
*IPCA Labs files Business Responsibility and Sustainability Report.* This is a routine regulatory disclosure under BRSR norms. No financial impact or operational updates disclosed. 📊 *STOCKS:* IPCALABORATORY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Sustainability
IPCA Labs publishes mandatory newspaper notice
*IPCA Labs publishes mandatory newspaper notice*. IPCA Laboratories Limited has released a copy of its newspaper publication as part of regulatory requirements. The filing contains no new financial or operational details. Such disclosures are routine and do not impact business operations. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
IPCA Laboratories publishes mandatory newspaper notice
*IPCA Laboratories publishes mandatory newspaper notice.* This is a routine regulatory disclosure required under corporate norms. Such filings are standard and do not indicate operational or financial changes. Investors need not take action. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.4K Cr 6.4% | ₹2.6K Cr 10.7% | ₹2.3K Cr 2.8% | ₹2.2K Cr 0.1% | ₹2.2K Cr 4.7% | ₹2.4K Cr 12.5% | ₹2.1K Cr 3.0% | ₹2.0K Cr |
| Op. Profit | ₹533 Cr 2.2% | ₹545 Cr 31.0% | ₹416 Cr 3.0% | ₹429 Cr 7.3% | ₹463 Cr 5.0% | ₹441 Cr 12.2% | ₹393 Cr 22.0% | ₹322 Cr |
| OPM | 22.0% 4.8% | 21.0% 16.7% | 18.0% 5.3% | 19.0% 9.5% | 21.0% 10.5% | 19.0% 0.0% | 19.0% 18.8% | 16.0% |
| Net Profit | ₹364 Cr 29.5% | ₹281 Cr 20.6% | ₹233 Cr 264.1% | ₹64 Cr 76.8% | ₹276 Cr 12.2% | ₹246 Cr 23.6% | ₹199 Cr 19800.0% | ₹1 Cr |
| EPS (₹) | 12.86 15.4% | 11.14 21.2% | 9.19 244.2% | 2.67 72.7% | 9.78 8.1% | 9.05 19.4% | 7.58 222.6% | 2.35 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9.6K Cr 7.9% | ₹8.9K Cr 16.1% | ₹7.7K Cr 23.5% | ₹6.2K Cr 7.0% | ₹5.8K Cr 7.5% | ₹5.4K Cr 16.8% | ₹4.6K Cr 23.3% | ₹3.7K Cr 15.0% | ₹3.3K Cr 3.2% | ₹3.2K Cr |
| Expenses | ₹7.6K Cr 6.2% | ₹7.2K Cr 13.1% | ₹6.3K Cr 20.2% | ₹5.3K Cr 17.9% | ₹4.5K Cr 16.4% | ₹3.8K Cr 3.4% | ₹3.7K Cr 21.8% | ₹3.1K Cr 8.8% | ₹2.8K Cr 3.6% | ₹2.7K Cr |
| Op. Profit | ₹2.0K Cr 15.0% | ₹1.7K Cr 30.7% | ₹1.3K Cr 42.1% | ₹932 Cr 29.7% | ₹1.3K Cr 14.6% | ₹1.6K Cr 71.7% | ₹904 Cr 30.1% | ₹695 Cr 52.7% | ₹455 Cr 0.9% | ₹451 Cr |
| OPM | 21.0% 10.5% | 19.0% 11.8% | 17.0% 13.3% | 15.0% 34.8% | 23.0% 20.7% | 29.0% 45.0% | 20.0% 5.3% | 19.0% 35.7% | 14.0% 0.0% | 14.0% |
| Other Income | ₹80 Cr 170.2% | ₹-114 Cr 770.6% | ₹17 Cr 86.2% | ₹123 Cr 127.8% | ₹54 Cr 8.5% | ₹59 Cr 9.2% | ₹65 Cr 16.1% | ₹56 Cr 36.6% | ₹41 Cr 272.7% | ₹11 Cr |
| Interest | ₹79 Cr 10.2% | ₹88 Cr 37.6% | ₹141 Cr 193.8% | ₹48 Cr 336.4% | ₹11 Cr 8.3% | ₹12 Cr 40.0% | ₹20 Cr 9.1% | ₹22 Cr 21.4% | ₹28 Cr 3.7% | ₹27 Cr |
| Depreciation | ₹418 Cr 5.0% | ₹398 Cr 11.5% | ₹357 Cr 36.3% | ₹262 Cr 12.9% | ₹232 Cr 11.0% | ₹209 Cr 0.5% | ₹210 Cr 15.4% | ₹182 Cr 2.2% | ₹178 Cr 2.9% | ₹173 Cr |
| PBT | ₹1.6K Cr 39.1% | ₹1.1K Cr 34.2% | ₹843 Cr 13.2% | ₹745 Cr 34.4% | ₹1.1K Cr 18.2% | ₹1.4K Cr 88.0% | ₹739 Cr 35.3% | ₹546 Cr 87.6% | ₹291 Cr 11.1% | ₹262 Cr |
| Tax % | 24.0% 20.0% | 30.0% 18.9% | 37.0% 8.8% | 34.0% 70.0% | 20.0% 17.6% | 17.0% 5.6% | 18.0% 5.3% | 19.0% 5.6% | 18.0% 30.8% | 26.0% |
| Net Profit | ₹1.2K Cr 50.8% | ₹785 Cr 50.1% | ₹523 Cr 9.2% | ₹479 Cr 46.2% | ₹890 Cr 22.0% | ₹1.1K Cr 88.9% | ₹604 Cr 36.7% | ₹442 Cr 84.9% | ₹239 Cr 22.6% | ₹195 Cr |
| EPS (₹) | 44.98 54.7% | 29.08 34.8% | 21.57 16.1% | 18.58 46.7% | 34.85 22.5% | 44.94 87.3% | 23.99 36.3% | 17.6 85.5% | 9.49 23.1% | 7.71 |
| Div Payout | 0.0% 100.0% | 14.0% 26.3% | 19.0% 13.6% | 22.0% 100.0% | 11.0% 22.2% | 9.0% 10.0% | 10.0% 11.1% | 9.0% 80.0% | 5.0% 16.7% | 6.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr 0.0% | ₹25 Cr |
| Reserves | ₹7.4K Cr 6.9% | ₹6.9K Cr 9.8% | ₹6.3K Cr 8.4% | ₹5.8K Cr 6.4% | ₹5.5K Cr 16.9% | ₹4.7K Cr 29.8% | ₹3.6K Cr 16.3% | ₹3.1K Cr 16.3% | ₹2.7K Cr 9.6% | ₹2.4K Cr |
| Borrowings | ₹1.3K Cr 6.2% | ₹1.4K Cr 5.2% | ₹1.4K Cr 2.9% | ₹1.5K Cr 83.5% | ₹807 Cr 204.5% | ₹265 Cr 47.1% | ₹501 Cr 7.7% | ₹465 Cr 26.0% | ₹628 Cr 12.3% | ₹716 Cr |
| Other Liabilities | ₹3.6K Cr 3.6% | ₹3.4K Cr 3.2% | ₹3.3K Cr 155.8% | ₹1.3K Cr 2.8% | ₹1.3K Cr 21.7% | ₹1.1K Cr 2.7% | ₹1.1K Cr 17.6% | ₹961 Cr 20.3% | ₹799 Cr 1.4% | ₹788 Cr |
| Total Liabilities | ₹12.3K Cr 4.4% | ₹11.7K Cr 5.8% | ₹11.1K Cr 28.7% | ₹8.6K Cr 12.9% | ₹7.6K Cr 25.9% | ₹6.1K Cr 15.4% | ₹5.3K Cr 15.6% | ₹4.5K Cr 10.5% | ₹4.1K Cr 3.9% | ₹4.0K Cr |
Assets | ||||||||||
| Fixed Assets | ₹4.4K Cr 2.4% | ₹4.3K Cr 6.3% | ₹4.6K Cr 65.5% | ₹2.8K Cr 13.8% | ₹2.4K Cr 16.7% | ₹2.1K Cr 0.6% | ₹2.1K Cr 6.1% | ₹1.9K Cr 0.7% | ₹2.0K Cr 1.5% | ₹2.0K Cr |
| CWIP | ₹777 Cr 24.9% | ₹622 Cr 81.3% | ₹343 Cr 145.0% | ₹140 Cr 54.2% | ₹306 Cr 30.2% | ₹235 Cr 76.7% | ₹133 Cr 101.5% | ₹66 Cr 9.6% | ₹73 Cr 23.2% | ₹95 Cr |
| Investments | ₹1.2K Cr 22.8% | ₹980 Cr 13.7% | ₹862 Cr 37.7% | ₹626 Cr 36.7% | ₹989 Cr 95.8% | ₹505 Cr 62.9% | ₹310 Cr 158.3% | ₹120 Cr 37.9% | ₹87 Cr 36.0% | ₹136 Cr |
| Other Assets | ₹5.9K Cr 0.6% | ₹5.9K Cr 10.0% | ₹5.3K Cr 4.6% | ₹5.1K Cr 30.1% | ₹3.9K Cr 20.6% | ₹3.3K Cr 18.1% | ₹2.8K Cr 13.8% | ₹2.4K Cr 20.9% | ₹2.0K Cr 14.7% | ₹1.7K Cr |
| Total Assets | ₹12.3K Cr 4.4% | ₹11.7K Cr 5.8% | ₹11.1K Cr 28.7% | ₹8.6K Cr 12.9% | ₹7.6K Cr 25.9% | ₹6.1K Cr 15.4% | ₹5.3K Cr 15.6% | ₹4.5K Cr 10.5% | ₹4.1K Cr 3.9% | ₹4.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.3K Cr 39.8% | ₹945 Cr 17.2% | ₹806 Cr 5.8% | ₹856 Cr 21.5% | ₹1.1K Cr 91.2% | ₹570 Cr 13.8% | ₹501 Cr 46.9% | ₹341 Cr 20.9% | ₹282 Cr 60.2% | ₹709 Cr |
| Investing CF | ₹-870 Cr 28.4% | ₹-1.2K Cr 67.6% | ₹-725 Cr 14.8% | ₹-851 Cr 63.3% | ₹-521 Cr 2.4% | ₹-509 Cr 208.5% | ₹-165 Cr 22.2% | ₹-135 Cr 9.4% | ₹-149 Cr 31.7% | ₹-218 Cr |
| Financing CF | ₹-283 Cr 48.8% | ₹-553 Cr 209.1% | ₹507 Cr 18.7% | ₹427 Cr 239.5% | ₹-306 Cr 123.4% | ₹-137 Cr 25.1% | ₹-183 Cr 40.8% | ₹-130 Cr 18.2% | ₹-159 Cr 65.6% | ₹-462 Cr |
| Net Cash Flow | ₹169 Cr 120.5% | ₹-823 Cr 240.0% | ₹588 Cr 36.1% | ₹432 Cr 63.6% | ₹264 Cr 447.4% | ₹-76 Cr 149.7% | ₹153 Cr 104.0% | ₹75 Cr 388.5% | ₹-26 Cr 189.7% | ₹29 Cr |
| Free Cash Flow | ₹551 Cr 1.5% | ₹543 Cr 56.5% | ₹347 Cr 8.7% | ₹380 Cr 48.0% | ₹731 Cr 163.9% | ₹277 Cr 14.0% | ₹322 Cr 56.3% | ₹206 Cr 40.1% | ₹147 Cr 68.3% | ₹463 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77d 3.8% | 80d 37.9% | 58d 1.8% | 57d 3.6% | 55d 22.5% | 71d 7.6% | 66d 1.5% | 67d 15.5% | 58d 1.8% | 57d |
| Inventory Days | 336d 4.0% | 350d 26.8% | 276d 18.1% | 337d 0.0% | 337d 14.6% | 294d 7.0% | 316d 10.5% | 286d 1.4% | 290d 0.3% | 289d |
| Days Payable | 111d 0.9% | 110d 32.5% | 83d 17.8% | 101d 27.9% | 140d 3.7% | 135d 12.3% | 154d 12.4% | 137d 5.4% | 130d 10.3% | 145d |
| Cash Conv. Cycle | 302d 5.9% | 321d 27.9% | 251d 14.3% | 293d 16.7% | 251d 9.6% | 229d 0.4% | 228d 5.6% | 216d 0.9% | 218d 9.0% | 200d |
| Working Capital Days | 101d 9.0% | 111d 56.3% | 71d 30.4% | 102d 1.0% | 103d 17.0% | 88d 0.0% | 88d 10.0% | 80d 8.1% | 74d 21.3% | 61d |
| ROCE | 15.0% 15.4% | 13.0% 18.2% | 11.0% 45.0% | 20.0% 35.5% | 31.0% 63.2% | 19.0% 18.8% | 16.0% 60.0% | 10.0% 11.1% | 9.0% 80.0% | 5.0% |
Source: Screener.in · Lower days = better efficiency
About IPCA Laboratories Limited
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
HealthcarePharmaceuticals & Biotechnology